Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."


Impact OF 2019 Physician Fee Schedule on Allergy and Sinus Services

Specialty Impact The conversion factor for 2019 will be $36.0391 and remains essentially flat.  The changes…

read more

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in…

read more

Fall Advocacy Update: USP 797, E/M Documentation and Payment

Revisions to USP Chapter 797 Open for Comment Since the United States Pharmacopeia (USP) released…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/01/19: Fellow Exam Application Deadline
Learn more

06/01/19: Research Grant Cycle
Learn more

06/01/19: Call For Scientific Abstracts Deadline
Learn more

06/7/19: Membership Application Deadline to be eligible for AAOA Member rate for the 2019 Basic Course

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

12/01/19: Research Grant Cycle
Learn more


Be a Part of the 2019 AAOA Annual Meeting!

AAOA is accepting Scientific Abstracts for in-person oral or poster presentation at the 2019 AAOA Annual Meeting in New Orleans, LA - September 13-15, 2019. Submit Scientific Abstract 


IFAR Impact Factor: 2.454


Now Available

Changes in Managing Practices


Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 Basic Course in Allergy & Immunology
June 27-29 | Minneapolis, MN
Learn More and Register

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Learn More and Register

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Save the Date

AAOA Clinical Insights
Learn More and Register


History of Allergy Treatment

The history of modern allergy treatment dates back to the early decades of the twentieth century with the demonstration of decreased response to grass pollens following conjunctival challenge done by Noon and Freeman.

Read More

News and Updates

CEO Update – Re·im·ag·ine

re·im·ag·ineverb reinterpret (an event, work of art, etc) imaginatively; rethink Reimagined, Reinvented, Reinvigorated….these are all…

read more

Americans May be Over-diagnosing Themselves with Food Allergies

"Food allergy is a costly, potentially life-threatening health condition that can adversely affect patients’ well-being". A study…

read more

FDA Approval of First and Only Digital Inhaler with Built-In Sensors

The Food and Drug Administration (FDA) has approved ProAir Digihaler (albuterol sulfate) inhalation powder for…

read more
Microscope 275984 640

New Drug Treatments for Allergies

Food allergies are a growing health concern with a significant increase in reported prevalence. Allergic reactions to food can produce life-threatening anaphylaxis. Peanut allergy in particular is a significant public health problem with no proven treatment nor a cure at the present time.

Peanut allergy often remains a life-long problem for many individuals, as less than 25% of peanut allergic patients are expected to regain tolerance. Current recommendations for management include strict avoidance and a prescription for an auto-injectable form of epinephrine.

The increase in prevalence of peanut allergy occurred during a period of time when there was conflicting guidance regard- ing preventative measures for the development of peanut allergy.

Prior to the year 2000, there were no guidelines regarding the timing for the introduction of peanut-containing products nor were there any purposeful strategies to delay the introduction of peanut-containing products to try to prevent the development of allergic disease. But in 2000, the American Academy of Pediatrics recommended that “solid foods should not be introduced into the diet of high-risk infants until 6 months of age…and peanuts…until years of age.”

This recommendation was reversed in 2008. At that time, AAP recommended that “the introduction of solid foods not be delayed past 4-6 months of age”. However they did not make any updated recommendations regarding the introduction of peanut-containing products.

The Learning Early About Peanut allergy (LEAP) study demonstrated that peanut-containing products can be safely introduced to high-risk infants between the ages of 4 to 11 months and that there is a monumental potential for peanut allergy prevention.

The National Institutes of Allergy and Infectious Diseases (NIAID) recently published an addendum guideline regarding the prevention of peanut allergy in the US based on the findings from the LEAP study. [Togias A et al. Addendum guidelines for the prevention of peanut allergy in the United States. J Allergy CliniImmunol.
2017 Jan;139(1):29-44.]

The NIAID-sponsored guidelines include the following three addendum recommendations:

Leave a Reply

Your email address will not be published. Required fields are marked *